DELTA-FLY-PHARMA
7.2.2024 12:01:32 CET | Business Wire | Press release
Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.
A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States. Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.
DFP-14927 is an amide bond of DFP-10917 to a carboxylic acid at the end of polyethylene glycol (PEG) with a molecular weight of 40,000, and it is extremely stable in human blood after intravenous administration, allowing for weekly treatment regimen. DFP-14927 is a drug delivery system (DDS) with a mechanism that allows selective release of DFP-10917 into cancer tissues by amidolysis of proteases that are highly expressed in them.
Compared to high molecular weight antibody-drug conjugates (ADCs), medium-sized PEG covalent conjugates are known to have retention in blood vessels around cancer and cancer cell membranes and higher permeability into tumors, and therefore, the concentration of DFP-10917 in cancer tissue can be measured by conventional analysis without the use of radioisotope technology.
Soon after the expected effective concentration of DFP-10917 in cancer tissue is confirmed in the study, we plan to conduct an expanded Phase I study, equivalent to a Phase II clinical trial, in patients with colorectal cancer who have failed existing approved drugs.
The composition of matter patent for DFP-14927 has been granted in the United States, Europe, Asian countries and others, which will enable global marketing of DFP-14927.
In collaboration with leading oncology hospitals in the U.S., we are considering the development of DFP-14927 in haematological cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in addition to solid tumors.
For our future global development and marketing strategy, we are considering collaboration with a major global pharmaceutical company that has strength and expertise in the oncology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207063856/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pure Lithium Announces Unprecedented Cycling Results From ItsAdvanced Anode™ Lithium Metal Battery Technology26.8.2026 13:00:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, today announced that our Advanced Anode™ battery, technology developed specifically to enable ultra-long cycling, has achieved more than 9,315 cycles. The cells continue to cycle in the Company's laboratory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826201214/en/ To the Company’s knowledge, no other lithium metal battery in development has achieved such results under equivalent testing conditions. The performance of the Company’s battery, achieved with negligible capacity fade, far exceeds today’s commercial lithium-ion battery cycling requirements across numerous applications, where performance typically ranges from 250 to 2,000 cycles, depending on the application. These results were achieved at 100% depth of discharge, and charge rates of 1C: 1C.1 “The results of Pure Lithium’s cycling performance are disruptive. Cycle life
Infopro Digital Automotive Highlights Its Industry-Leading Datasets at Automechanika 202626.8.2026 10:02:00 CEST | Press release
Infopro Digital Automotive, leader in data and software for the automotive market, announces its participation in Automechanika 2026, the world’s leading trade fair for the automotive industry. After completing several significant acquisitions over the past years, including Eucon, GiPA, and Aurelis last September, the company will attend this year’s trade show with a consolidated offering, built upon its trusted industry-leading datasets. Infopro Digital Automotive now addresses every automotive vertical from independent workshops to parts, tyres and car manufacturers, through the whole network of aftermarket distribution professionals, thus delivering to them key data and integrated digital solutions to power strategic decisions at every step of the vehicle lifecycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826133342/en/ Infopro Digital Automotive’s unmatched dataset portfolio will be presented at Automechanika 20
NIPPON KINZOKU Establishes Mass Production of Ultra-Thin and Narrow Stainless Steel for Insulin Needles26.8.2026 10:01:00 CEST | Press release
- Addressing the Global Rise in Diabetes - NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491) is pleased to announce the commencement of mass production for its "Ultra-thin and narrow-width stainless steel" optimized for laser welding in ultra-fine insulin needles. In response to growing global demand, the company has established a stable supply system for these high-quality materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826770424/en/ The scale of the global diabetes crisis is expanding. In line with this trend, the global demand for insulin needles continues to escalate. Furthermore, insulin delivery is evolving toward "painless" experiences that reduce patient burden. Modern designs prioritize minimizing pain and bruising, leading to the widespread adoption of ultra-fine needles. This trend is further supported by the growing popularity of compact, portable pe
VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data26.8.2026 10:00:00 CEST | Press release
VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial. VirTus has worked on the APL-10456 programme for more than five years, conducting more than 20 preclinical studies to support the selection, development and progression of the candidate, testing the cross-species immunogenicity and efficacy. This work included evaluating the efficacy of several vaccine candidates in mouse models of rhinovirus infection, helping to select APL-10456 and establish early proof of concept and generating preclinical evidence that informed its progression into first-in-human clinical development. APL-10456 is a first-in-class, adjuvanted recombinant protein subunit
Xsolla President Chris Hewish Debuts “Durable Advantage” at Gamescom 202626.8.2026 09:00:00 CEST | Press release
Book Draws on Chris Hewish’s Three Decades of Leadership in the Global Games Industry, Grounded in “Renters vs. Owners” Theory and Five-Pillars for Scaling and Succeeding Xsolla, a leading global commerce company, today announced Durable Advantage: Five Pillars of the Modern Game Business, a new book authored by Chris Hewish, President of Xsolla, launching at Gamescom 2026 in Cologne. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826628682/en/ Graphic: Xsolla Xsolla's integrated strategy brings together global payments, direct-to-consumer commerce, backend infrastructure, and AI-powered development tools into a unified operating model designed to help studios launch, operate, and scale more efficiently. Rather than relying on disconnected commerce, engagement, and backend systems, developers can activate new capabilities through a common platform foundation that reduces complexity, accelerates deployment, and creates a m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom